Previous 10 | Next 10 |
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company - Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising invest...
Gilead Sciences (GILD) celebrated the recent FDA approval of its COVID-19 antiviral drug remdesivir. However, many scientists remain skeptical about its effectiveness with mixed evidence on the drug, the stock has been on a downward trajectory since its April highs. Find out if GILD can rebou...
Arena Pharmaceuticals has an impressive pipeline of compounds, and its trials are progressing well now, despite the impact of COVID-19. After its equity offering in early June at $50 per share, shares topped $60 and have not looked back. The 52-week high of $86.48 was set on the 12th....
NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community - New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis - Arena sponsored sympos...
bluebird bio announces European acceptance of eli-cel gene therapy. Arena Pharmaceuticals completes enrollment for CAPTIVATE trial. Mesoblast suffers a setback as FDA rejects cell therapy application. For further details see: bluebird's European MAA, And Other News: The ...
Arena Pharmaceuticals (ARNA) has completed full enrollment of the Phase 2b CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2), for the potential treatment of abdominal pain in irritable bowel syndrome ((I...
Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome - Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C)...
While the market has mainly sold-off this month, four biotech stocks have showed strength in anticipation of successful drug candidates: Arena Pharmaceuticals (ARNA), Fate Therapeutics (FATE), Kura Oncology (KURA), and Stoke Therapeutics (STOK). The biotech sector has received a lot of at...
Arena Pharmaceuticals, Inc. (ARNA) Jefferies Next Generation IBD Therapeutics Virtual Summit September 23, 2020 13:45 ET Corporate Participants Amit Munshi - Chief Executive Officer Conference Call Participants Chris Howerton - Jefferies Presentation Chris Howerton Hi, everyone. My name is Ch...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...